Last reviewed · How we verify

Anti-human Thymoglobulin — Competitive Intelligence Brief

Anti-human Thymoglobulin (Anti-human Thymoglobulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antithymocyte globulin (ATG). Area: Immunology.

marketed Polyclonal antithymocyte globulin (ATG) T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-human Thymoglobulin (Anti-human Thymoglobulin) — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Anti-human thymoglobulin is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells in the circulation and lymphoid tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Anti-human Thymoglobulin TARGET Anti-human Thymoglobulin Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Polyclonal antithymocyte globulin (ATG) T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
rabbit ATG（Sanofi/Genzyme） rabbit ATG（Sanofi/Genzyme） Chinese PLA General Hospital marketed Polyclonal antithymocyte globulin (ATG) Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR, and others)
ATG Fresenius ATG Fresenius University Hospital, Basel, Switzerland marketed Polyclonal antithymocyte globulin (ATG) T-cell surface antigens (CD2, CD3, CD4, CD8, CD25, HLA-DR)
Rabbit ATG, (Genzyme) Rabbit ATG, (Genzyme) Jinan Military General Hospital marketed Polyclonal antithymocyte globulin (ATG) T-cell surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
Thymoglobulin (ATG) Thymoglobulin (ATG) M.D. Anderson Cancer Center marketed Polyclonal antithymocyte globulin (ATG) Multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR)
Thymoglobuline Genzyme Thymoglobuline Genzyme University Hospital, Basel, Switzerland marketed Polyclonal antithymocyte globulin (ATG) Multiple T-cell surface antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, and others)
Flu-ATG Flu-ATG Cooperative Study Group A for Hematology phase 3 Polyclonal antithymocyte globulin (ATG) T lymphocytes (CD2, CD3, CD4, CD8, and other T-cell surface antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antithymocyte globulin (ATG) class)

  1. University Hospital, Basel, Switzerland · 2 drugs in this class
  2. Chinese PLA General Hospital · 1 drug in this class
  3. Cooperative Study Group A for Hematology · 1 drug in this class
  4. Jinan Military General Hospital · 1 drug in this class
  5. M.D. Anderson Cancer Center · 1 drug in this class
  6. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-human Thymoglobulin — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-human-thymoglobulin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: